Startup company Xinnate has developed a wound gel in collaboration with a researchers group in Lund, which has shown in animal studies that the gel is significantly more effective than conventional therapies. The gel is based on a completely new approach to wound healing through the body’s innate mechanisms, which has now been described and published in the journal Science Translational Medicine. Clinical studies are planned to begin in the second half of 2020.
Life-threatening complications from wounds are a major and growing global problem, both because current methods are inadequate and because antibiotics, today's lifeline, do not always work due to the development of multi-resistant bacteria.
Professor Artur Schmidtchen and his team at Lund University have studied natural endogenous mechanisms and substances that are involved in our normal wound healing.
“Based on this research, we developed a gel that reduces the quantity of harmful bacteria while having an immunomodulatory effect and reducing the high inflammation that bacteria cause in the wound, which inhibits wound healing," he says.
Using in vivo models, the study compares the gel with current conventional methods and the results, which show that the gel provides faster and better wound healing than current conventional methods, have now been published in Science Translational Medicine. Current treatments – using antibiotics and antiseptics such as silver or polyhexanide – are solely antibacterial and do not affect the subsequent harmful inflammatory process during wound healing.
“The data that have now been published show that the gel is effective at both preventing and treating infections in wounds. The discovery could lead to new sustainable wound healing treatments. It can prevent infections, improve the healing process and reduce dependence on antibiotics. At the same time, it can reduce the cost of care [EO1] [s2] since many of today’s complications require hospitalization,” says Helene Hartman, CEO of Xinnate.
The patent-pending gel is being developed in collaboration with Xinnate, a company in the SmiLe business incubator in Medicon Village in Lund and a subsidiary of in2cure. Xinnate is now working to have the gel approved for use in clinical studies for patients with burn injuries. The studies are planned to begin in the second half of 2020.
For information about the product please contact: Helene Hartman, CEO, Xinnate Tel.: +46 (0)725-120312, e-mail: email@example.com
Xinnate focuses on developing pharmaceutical concepts for external applications in skin and wound care, surgery and biomaterials. The company develops products based on one of our natural defense mechanisms that has been shown to have a unique and sustainable anti-inflammatory and antibacterial effect regardless of multi-resistance. Xinnate is a member of SmiLe Incubator in Medicon Village in Lund, Sweden and is a subsidiary of in2cure. www.Xinnate.com